Hoxb8 regulates expression of microRNAs to control cell death and differentiation

Cell Death and Differentiation

Volumn 20, Issue 10, 2013, Pages 1370-1380

  Salmanidis, M ^a,b,c   Brumatti, G ^a,b   Narayan, N ^a,b   Green, B D ^a,b,c   Van Den Bergen, J A ^c   Sandow, J J ^a,b   Bert, A G ^d   Silke, N ^a   Sladic, R ^d   Puthalakath, H ^e   Rohrbeck, L ^a,b   Okamoto, T ^a,b,f   Bouillet, P ^a,b   Herold, M J ^a,b   Goodall, G J ^d,g   Jabbour, A M ^a,b   Ekert, P G ^a,b,c  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d CENTRE FOR CANCER BIOLOGY   (Australia)

^e LA TROBE UNIVERSITY   (Australia)

^f OSAKA UNIVERSITY   (Japan)

^g UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Apoptosis; Hoxb8; interleukin 3; microRNA

Indexed keywords

BIM PROTEIN; INTERLEUKIN 3; MICRORNA; PROTEIN BAK; PROTEIN BAX;

3' UNTRANSLATED REGION; ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL CYCLE ARREST; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; HOX GENE; HOXB8 GENE; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL;

3' UNTRANSLATED REGIONS; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; GENE EXPRESSION REGULATION; HOMEODOMAIN PROTEINS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICRORNAS; PROTO-ONCOGENE PROTEINS; TRANSFECTION;

EID: 84883798802     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.92     Document Type: Article

References (50)

1. McGinnis W, Garber RL, Wirz J, Kuroiwa A, Gehring WJ. A homologous protein-coding sequence in drosophila homeotic genes and its conservation in other metazoans. Cell 1984; 37: 403-408.
2. Phelan M, Rambaldi I, Featherstone M. Cooperative interactions between HOX and PBX proteins mediated by a conserved peptide motif. Mol Cell Biol 1995; 15: 3989-3997.
3. Shen WF, Montgomery JC, Rozenfeld S, Moskow JJ, Lawrence HJ, Buchberg AM et al. AbdB-like Hox proteins stabilize DNA binding by the Meis1 homeodomain proteins. Mol. Cell. Biol 1997; 17: 6448-6458. (Pubitemid 27451190)
4. Argiropoulos B, Humphries RK. Hox genes in hematopoieis and leukemogenesis. Oncogene 2007; 26: 6766-6776.
5. Antonchuk J, Sauvageau G, Humphries RK. HoxB4 induced expansion of adult hematopoietic stem cells ex vivo. Cell 2002; 109: 39-45. (Pubitemid 34327515)
6. Perkins AC, Cory C. Conditional immortalization of mouse myelomonocytic, megakaryocytic and mast cell progenitors by the Hox-2.4 homeobox gene. EMBO J 1993; 12: 3835-3846. (Pubitemid 23282760)
7. Thorsteinsdottir U, Mamo A, Kroon E, Jerome L, Bijl J, Lawrence HJ et al. Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood 2002; 99: 121-129.
8. Lawrence HJ, Helgason CD, Sauvageau G, Fong S, Izon DJ, Humphries RK et al. Mice bearing a targeted interruption of the homeobox gene HOXA9 have defects in myeloid, erythroid, and lymphoid hematopoiesis. Blood 1997; 89: 1922-1930. (Pubitemid 27132106)
9. Izon DJ, Rozenfeld S, Fong ST, Komuves L, Largman C, Lawrence HJ. Loss of function of the homeobox gene Hoxa-9 perturbs early T-cell development and induces apoptosis in primitive thymocytes. Blood 1998; 92: 383-393.
10. Perkins A, Kongsuwan K, Visvader J, Adams JM, Cory S. Homeobox gene expression plus autocrine growth factor production elicits myeloid leukaemia. PNAS 1990; 87: 8398-8402.
11. Blatt C, Aberdam D, Schwartz R, Sachs L. DNA rearrangement of a homeobox gene in myeloid leukaemic cells. EMBO J 1988; 7: 4283-4290.
12. Kongsuwan K, Allen J, Adams JM. Expression of Hox2.4 homeobox gene directed by proviral insertion in myeloid leukemia. Nucleic Acids Res 1989; 17: 1881-1892. (Pubitemid 19084244)
13. Scholl C, Bansal D, Dohner D, Eiwen D, Huntly BJP, Lee BH et al. The homeobox gene CDX2 is aberrangly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. J Clin Invest 2007; 117: 1037-1048. (Pubitemid 46556760)
14. Ekert PG, Jabbour AM, Manoharan A, Heraud JE, Yu J, Pakusch M et al. Cell death provoked by loss of interleukin-3 signaling is independent of Bad, Bim and PI3 kinase, but depends in part on Puma. Blood 2006; 108: 1461.
15. Ekert PG, Read SH, Silke J, Marsden VS, Kaufmann H, Hawkins CJ et al. Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factor-deprived or drugtreated cells die. J Cell Biol 2004; 165: 835-842. (Pubitemid 38821974)
16. Fujino T, Yamakazi Y, Largaespada DA, Jenkins NA, Copeland NG, Hirokawa K et al. Inhibition of myeloid differentiation by Hoxa9, Hoxb8 and Meis homeobox genes. Exp Hematol 2001; 29: 856-863. (Pubitemid 32600918)
17. Knoepfler PS, Sykes DB, Pasillas M, Kamps MP. HoxB8 requires its Pbx-interaction motif to block differentiation of primary myeloid progenitors and of most cell line models of myeloid differentiation. Oncogene 2001; 20: 5440-5448. (Pubitemid 32889480)
18. Faber J, Krivtsov AV, Stubbs MC, Wright R, Davis TN, van den Heuvel-Eibrink M et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 2009; 113: 2375-2385.
19. Potts MB, Wang DP, Cameron S. Trithorax, Hox, and TALE-class homeodomain proteins ensure cell survival through repression of the BH3-only gene egl-1. Dev Biol 2009; 329: 374-385.
20. Liu H, Strauss TJ, Potts MB, Cameron S. Direct regulation of egl-1 and of programmed cell death by the Hox protein MAB-5 and by CEH-20, a C. elegans homolog of Pbx1. Development 2005; 133: 641-650.
21. Jabbour AM, Heraud JE, Daunt CP, Kaufmann T, Sandow J, O?Reilly LA et al. Puma indirectly activates Bax to cause apoptosis in the absence of Bid or Bim. Cell Death Differ 2009; 16: 555-563.
22. Sandow JJ, Jabbour AM, Condina MR, Daunt CP, Stomski FC, Green BD et al. Cytokine receptor signaling activates an IKK-dependent phosphorylation of PUMA to prevent cell death. Cell Death Differ 2012; 19: 633-641.
23. Wang GG, Calvo KR, Pasillas MP, Sykes DB, Hacker H, Kamps MP. Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8. Nat Methods 2006; 3: 287-293.
24. Lindsten T, Thompson CB. Cell death in the absence of Bax and Bak. Cell Death Differ 2006; 13: 1272-1276. (Pubitemid 44057458)
25. Bouillet P, Metcalf D, Huang DCS, Tarlinton DM, Kay TW, Kontgen F et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis and to preclude autoimmunity. Science 1999; 286: 1735-1738. (Pubitemid 129515880)
26. Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008; 9: 405-414. (Pubitemid 351405110)
27. Gocek E, Wang X, Liu X, Liu C-G, Studzinski GP. MicroRNA-32 upregulation by 1, 25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis. Cancer Res 2011; 71: 6230-6239.
28. Qian L, Van Laake LW, Huang Y, Liu S, Wendland MF, Srivastava D. miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. J Exp Med 2011; 208: 549-560.
29. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ et al. Targeted deletion reveals essential and overlapping functions of the miR-17B92 family of miRNA clusters. Cell 2008; 132: 875-886. (Pubitemid 351312807)
30. Grimson A, KK-H Farh, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007; 27: 91-105. (Pubitemid 46991392)
31. Garcia DM, Baek D, Shin C, Bell GW, Grimson A, Bartel DP. Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat Struct Mol Biol 2011; 18: 1139-1146.
32. Wong P, Iwasaki M, Somervaille TCP, Ficara F, Carico C, Arnold C et al. The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res 2010; 70: 3833-3842.
33. Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev 2009; 23: 2839-2849.
34. Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, Forloni M et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One 2008; 3: e2236.
35. Jabbour AM, Daunt CP, Green BD, Vogel S, Gordon L, Lee RS et al. Myeloid progenitor cells lacking p53 exhibit delayed up-regulation of Puma and prolonged survival after cytokine deprivation. Blood 2010; 115: 344-352.
36. O?Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435: 839-843. (Pubitemid 40839736)
37. Yekta S, Shih I-h, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science 2004; 304: 594-596. (Pubitemid 38541919)
38. Tagawa H, Seto M. A microRNA cluster as a target of genomic amplification in malignant lymphoma. Leukemia 2005; 19: 2013-2016. (Pubitemid 41554018)
39. Rao E, Jiang C, Ji M, Huang X, Iqbal J, Lenz G et al. The miRNA17B92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia 2005; 26: 1064-1072.
40. Diosdado B, van de Wiel MA, Terhaar Sive Droste JS, Mongera S, Postma C, Meijerink WJHJ et al. MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br J Cancer 2009; 101: 707-714.
41. Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261. (Pubitemid 43271657)
42. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435: 828-833. (Pubitemid 40839734)
43. Ziemin-van der Poel S, McCabe NR, Gill HJ, Espinosa R, Patel Y, Harden A et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci USA 1991; 88: 10735-10739. (Pubitemid 21915912)
44. Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 2003; 17: 2298-2307. (Pubitemid 37128644)
45. Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 2004; 101: 6164-6169. (Pubitemid 38520545)
46. Inomata M, Tagawa H, Guo Y-M, Kameoka Y, Takahashi N, Sawada K. MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood 2009; 113: 396-402.
47. Nagel S, Venturini L, Przybylski GK, Grabarczyk P, Schmidt CA, Meyer C et al. Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia. Leuk Lymphoma 2009; 50: 101-108.
48. Thomson DW, Bracken CP, Goodall GJ. Experimental strategies for microRNA target identification. Nucleic Acids Res 2011; 39: 6845-6853.
49. Yeap YYC, Ng IHW, Badrian B, Nguyen TA, Yip YY, Dhillon AS et al. c-Jun N-terminal kinase/c-Jun inhibits fibroblast proliferation by negatively regulating the levels of stathmin/oncoprotein Biochem J 2010; 430: 345-354.
50. van Delft MF, Wei AH, Mason KD, Vandengerg CJ, Chen L, Czabotar PE et al. The BH3 mimetic, ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389-399. (Pubitemid 44711953)